Rx-360 Summary of FDA's Supply Chain Security Pilot Programme
On 20 August, FDA announced the initiation of a pilot import program. The Secure Supply Chain Pilot Program will launch in 2014 and, pending the outcome, it may become permanent.
FDA is seeking 100 applicants for the pilot program with no more than five drug products per applicant. This programme is associated with Section 713 of FDASIA that “…authorises FDA to require the submission of drug compliance information as a condition of granting admission to imported drugs…” including generation of regulations that may allow FDA to treat companies differently based on their compliance history and type of import. This may permit expedited import of materials by and from highly compliant companies.
The FDA announcement specifies 12 requirements that must be met by applicants to the pilot program, including
• Completion of the necessary application
• The ultimate consignee must be in compliance with FDA registration and listing requirements and GMPs, including compliance during the past 3 years
• For imported finished dosage form, the consignee must be identified in the approved NDA/ANDA
• For imported API, the source must be identified in the NDA/ANDA and be used to manufacture an FDA approved product.
• The foreign manufacturer of finished dosage form or API must be in compliance with the FD&C Act
• The applicant must have an adequate system in place to effect a recall or field correction
• Applicants must have an adequate system to comply with record keeping requirements specified in the FD&C Act and its implementing regulations.
Related News
-
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News US FDA grants priority review for Eisai and Biogen's Alzheimer's drug
Decision by US drug regulator on lecanemab expected by early next year -
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor... -
News Pharma Explained: What is Quality Risk Management & cGMPs?
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPHI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta... -
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations
Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPHI Festival of Pharma -
News Successful MHRA regulatory inspection for Scottish CMO Symbiosis
Inspection conducted remotely using video-conferencing and an online private document sharing platform.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance